Pioneering prescription digital therapeutics
Reversing insulin resistance with AI-driven lifestyle modification.
Get in touchOur purpose
Empowering people to restore their cardiometabolic health.
1 in 3 adults suffers from more than one chronic condition. We create digital therapies that treat the cause, not the symptoms. One habit at a time. Without side effects.
Robust DTx platform with a human touch
Exceptional engagement rate proven by thousands of users
Clinically proven outcomes
The clinical effect of our digital therapeutics is comparable to modern antidiabetic drugs. We are committed to rigorous validation in clinical studies.
more patients achieved the recommended level of HbA1c compared to the standard of care
of patients report a significant
weight reduction
Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program
A Peer Reviewed Randomized Controlled Trial. Nutrients journal, 2022. (5-Year Impact Factor: 7.185)
University Olomouc
Impact of a Digital Lifestyle Intervention on Diabetes Self-Management
A Peer Reviewed Observational Study. Nutrients journal, 2022. (5-Year Impact Factor: 7.185).
Technische Universität Dresden
The biggest pharmaceutical players augment their pharmacotherapy with Vitadio
What are the benefits of combining medication with digital therapeutics?- Achieving a superior reduction in HbA1c and body weight
- Improving quality of life
- Driving better adherence to treatment
- Providing differentiation in the market
How it started
Our story began in 2019 when our 4 founders decided to innovate type 2 diabetes care and provide best-in-class therapy by combining the power of artificial intelligence and evidence-based medicine.
Today, Vitadio, with headquarters in Prague and Berlin, offers digital therapeutics for type 2 diabetes and prediabetes across three European countries, with ongoing expansion efforts.
Featured in
Join our purpose-driven team that tackles the biggest challenges in healthcare.